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1. Introduction 
The aims of this chapter are to describe: 
1. the actual role of tumour markers in the follow-up for breast cancer; 
2. the use of tumour markers as an indicator of positron emission tomography (PET) 
execution and as a predictor of PET positivity;  
3. the diagnostic accuracy of tumour markers, PET or PET/computed tomography (CT), 
and their combination; 
4. the clinical and therapeutic impacts of tumour markers and nuclear medicine imaging; 
5. the future prospective for breast cancer follow-up. 
In this chapter we will bring together various reports on these subjects, and propose the use 
of tumour markers as a guide for the use of PET/CT, in particular to define the risk 
categories for breast cancer patients and the correct algorithm for follow-up.  
2. Background  
The definition of tumour markers is extremely broad, as tumour cells may express certain 
molecules at different rates from normal cells. These substances are released into the blood 
stream or other biological fluids. It would be justified to assert that biochemical 
measurement of the serum marker level in patients with a cancer diagnosis can give 
dynamic information about the clinical evolution of neoplastic processes and reflect the 
biological rather than the structural behaviour of the tumour. Even though their use in the 
follow-up of cancer patients has the advantages of being simple, objective, reproducible and 
cost-effective, the main problem is the lack of both sensitivity and specificity. In fact, the 
optimal tumour markers should only increase in the presence of a tumour and in the early 
phases of tumour growth, but none of the tumour markers currently available completely 
meet these requirements. 
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2.1 The role of serum markers in the management of patients with breast cancer 
In breast cancer, the role of serum markers has remained unclear. Their potential uses in 
breast cancer include early diagnosis, determination of the prognosis, prediction of response 
or resistance to specific therapies, monitoring of the treatment in patients with metastatic 
disease and follow-up after primary treatment. Cancer antigen 15.3 (CA 15.3) and CA 27.29 
are well-characterized assays that allow the detection of circulating MUC-1 antigen in 
peripheral blood. Carcinoembryogenic antigen (CEA) levels are less commonly elevated 
than the levels of MUC-1 assays, CA 27.29 or CA 15.3. Only 50% - 60% of patients with 
metastatic disease will have elevated CEA levels (sensitivity varies from 30 - 70% for visceral 
and skeletal metastases, with a positive predictive value ranging from 18% - 26%, 
respectively) compared to 75% - 90% who have elevated levels of the MUC-1 antigens. For 
this reason CA 15.3 is considered to be more specific than CEA in monitoring breast cancer 
evolution, and this latter marker is usually considered a poor predictor of breast cancer 
recurrence.  
Unfortunately, aspecific elevation of both CEA and CA 15.3 can also be found in patients 
with inflammatory disease (e.g. diverticulitis, bronchitis), autoimmune disease (e.g. 
sarcoidosis) and other benign diseases (e.g. hepatitis, cirrhosis, hypothyroidism) in the 
presence of lung, gastrointestinal or neuroendocrine tumours, as well as in smokers and the 
elderly (Lumachi et al., 2004; Duffy et al., 2006). 
Many attempts have been made in the past to provide evidence of the ability of CA 15.3 
elevation at diagnosis to predict shorter survival rates, both disease-free and overall, but 
results are conflicting, and statistical significance was often lost at multivariate analysis. CA 
15.3 is not therefore an independent prognostic factor in predicting the risk of recurrence, 
and it has no clinical value in the early detection of local recurrence or second cancer, due to 
low sensitivity in the presence of localized disease. The importance of detecting locally-
recurrent breast cancer at an early stage arises from the fact that an increasing rate of distant 
metastases and a poor outcome are usually associated with local failure in breast cancer 
therapy (Fortin et al., 2006). 
2.2 Monitoring response to treatment in breast cancer 
Traditionally, the response to systemic treatment in patients with metastatic breast cancer is 
evaluated using criteria from the International Union Against Cancer (UICC). The UICC 
criteria includes physical examination, measurement of lesions, radiology and isotope 
scanning (Hayward et al., 1977). Two multi-centre trials, however, have shown that changes in 
serial concentrations of tumour markers correlate with therapy response based on the UICC 
criteria (Robertson et al., 1999; Van Dalen et al., 2004). Tampellini et al. (Tampellini et al., 2006) 
performed a large single institution study with the aim of measuring serum CA 15.3 at 
baseline, and at three and six months during anthracycline-based first-line chemotherapy in 
526 patients with advanced breast cancer who had been prospectively enrolled in five phase II-
III trials. A significant relationship between changes in CA 15.3 level and clinical response was 
found; and at multivariate analysis, CA 15.3 variation at six months was found to be an 
independent prognostic indicator for time to progression and overall survival. The early 
detection of disease progression and of resistance to ongoing treatment is considered an 
important issue in metastatic patients, because the target of therapy in this patient subset is the 
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palliation. Therefore, tolerability and quality of life are fundamental in therapeutic decisions, 
and should be balanced against potential gains in disease regression and global survival. A 
lead time of 1-10 months has been reported when the assessment of treatment response, 
according to the UICC criteria, was made using blood markers. This finding can be explained 
by the fact that the international criteria reflect structural change: a metastasis needs to reach a 
significant size to be detectable by radiological exams; otherwise, blood tumour markers reflect 
the total tumour burden which is be measurable from the summation of numerous sub-clinical 
metastases (Cheug et al., 2000). Tumour markers can give important information concerning 
the response of cancer to ongoing treatment, even if they cannot be used alone for monitoring 
therapy in patients with advanced breast cancer. An increase of tumour markers can be 
detected even when the tumour has been responding to treatment; this phenomenon is known 
as a “tumour marker spike” (Yasasever et al., 1997; Hayes et al., 1988) and represents a 
transient increase in serum CA 15.3 levels following the initiation of effective therapy for 
metastatic disease. The peak usually occurs 15-30 days after the initiation of treatment, 
although spikes may last as long as 90 days. The return to a normal value, or to below baseline 
level, is consistent with response to therapy. 
Although the studies available show encouraging data, the American Society of Clinical 
Oncology (ASCO) panel stated that CA 15.3 and CEA alone cannot be employed to define 
response to treatment (Harris L et al., 2007). Conversely, both the European Group on 
Tumour Markers (EGTM) and the National Academy of Clinical Biochemistry (NACB) 
panels recommend the use of CA 15.3 for monitoring therapy in patients with metastatic 
breast cancer (Molina et al., 2005; Fleisher et al., 2002).  
2.3 Tumour markers and surveillance after primary treatment 
In breast cancer, not only the use of serum markers, but also the follow-up in general, is not 
generally established. Two multi-centre randomized prospective trials (The GIVIO 
Investigators, 1994 and Rosselli et al. 1994), and a systematic review (Collins et al., 2004), 
compared the outcome in patients followed with clinical visits and mammography, with those 
followed up with an intensive regime including radiology and traditional laboratory testing. 
All reports concluded that the use of an intensive follow-up programme failed to improve 
either the outcome or quality of life. However, in these studies, some limitations with respect 
to management of patients with breast cancer are reported: 1) the use of old and insensitive 
biochemical tests and/or radiological exams, and 2) the unavailability of new treatments such 
as taxanes, aromatase inhibitors and trastuzumab for recurrence treatment (Duffy et al., 2006). 
The current ASCO guidelines recommend only careful history taking, physical examination 
and a regular mammography for appropriate detection of breast cancer recurrence 
(Khatcheressian et al., 2006). The purpose of an intensive follow-up with radiological exams 
and serial tumour markers determination is the early detection of recurrent or metastatic 
disease, which  can enhance the chances of appropriate treatment and survival. Although 
serial CA 15.3 concentrations can anticipate the diagnosis of recurrent/metastatic disease with 
a lead time of between 2 - 9 months (Safi et al., 1989; Colomer et al., 1989; Nicolini et al., 1991; 
Repetto et al., 1993; al-Jarallah et al., 1993; Sölétormos et al., 1993), it is unclear whether the 
introduction of early treatment based on this lead time actually improves disease-free survival, 
overall survival, or quality of life for patients. In an attempt to address these issues, several 
small-scale studies have been carried out. In one of the first of these, Jager et al. (Jager et al., 
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1995) randomized patients who had no evidence of metastatic disease, with increasing 
concentrations of tumour markers (CA 15-3 or CEA) to receive (n = 21) or not receive (n = 26) 
medroxyprogesterone acetate, reporting that for the untreated patients, the median time 
interval between increase in marker concentration and detectable metastasis was four months, 
while for the treated patients it was >36 months. Kovner et al. (Kovner et al., 1994) randomized 
asymptomatic patients with increasing mammary cancer antigen concentrations to receive (n = 
23) or not receive tamoxifen (n = 26). After an average follow-up of 11 months, 7 out of 29 
patients (24%) in the control group had relapsed, whereas none of the 23 patients who had 
received treatment developed a recurrence (p= 0.012). Nicolini et al. (Nicolini et al., 1997; 2004) 
compared the outcomes in 36 asymptomatic patients who received salvage treatment based on 
tumour marker increases (CA 15-3, CEA, or TPA) with 32 patients who were given treatment 
only after radiologic confirmation of metastasis. Survival from both the time of mastectomy 
and salvage treatment was significantly improved in the group with tumour marker–guided 
treatment than in those treated conservatively. These studies suggested that an early treatment 
of recurrent or metastatic disease based exclusively on an increase of tumour markers can 
improve the outcome, but the numbers of patients in the studies are too small to recommend 
this approach. In fact, the ASCO (Harris et al. 2007), the European Society of Clinical Oncology 
(Kataja et al., 2009) and the National Comprehensive Cancer Network (NCCN 2010) do not 
recommend their use. Furthermore, in some studies the value of tumour markers resulted 
positive in two thirds of patients with a recurrence of disease, while for the remaining third it 
either did not become positive or became positive late, thus showing both low sensitivity and 
positive predictive value (PPV) (Duffy et al., 2006; Anonymous et al., 1996). Therefore, in 
patients suspected of having a breast cancer relapse, low levels of markers do not exclude the 
presence of malignancy; whereas, high levels of markers almost certainly indicate the presence 
of metastatic disease (Soletormos et al., 2004; Given et al., 2000). 
Sutterlin et al. (Sutterlin et al., 1999) evaluated 1228 serum samples from 664 women with a 
history of breast cancer, with accuracy and predictive values of CEA and CA 15.3. Seventy-
six of the 664 women had had a relapse; the diagnostic accuracies of CEA and CA 15.3 were 
83% and 88%, with a PPV of 27% and 47% and a negative predictive value (NPV) of 91% 
and 93%, respectively. The low PPV and sensitivity of CEA and CA 15.3 clearly limit their 
clinical utility. The effectiveness of routine determinations during the follow-up seems 
questionable, and the choice of the best marker is also unclear. Given et al. compared the 
diagnostic accuracy of CA 15.3, CEA and tissue polypeptide antigen (TPS) in the detection 
of breast cancer recurrences in 1448 patients (Given M et al., 2000). The results are 
summarized in Table 1: 
 
 Sensitivity Specificity PPV NPV 
 Vis Bone Loc Vis Bone Loc Vis Bone Loc Vis Bone Loc 
CA 
15.3 
68% 69% 23% 92% 92% 86% 47% 54% 22% 94% 96% 86% 
TPS 64% 51% 17% 88% 88% 79% 25% 21% 16% 91% 93% 78% 
CEA 27% 46% 11% 92% 92% 76% 18% 26% 13% 90% 92% 84% 
Vis: visceral recurrence; Bone: bone recurrence; Loc: loco-regional recurrence; PPV: positive predictive 
value; NPV: negative predictive value 
Table 1. A summary of results based on lesion sites 
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As shown in Table 1, the role of CA 15.3 as the tumour marker remains the better choice as 
it is useful as a predictor of recurrence in breast cancer, although it has low sensitivity and 
PPV for loco-regional recurrence, and neither TPS nor CEA complemented its sensitivity or 
PPV. In conclusion, even if expert panels have different positions on the matter, the actual 
main utility of CEA and CA 15.3 is in monitoring patients with advanced breast cancer, 
especially in women with non-valuable disease. Insufficient data has been published to 
suggest that the use of tumour markers during follow-up can change the course of breast 
cancer patients. Prospective randomized trials are needed to answer this question 
definitively. 
3. Why is PET associated with tumour markers? 
Multiple metastatic disease and a large tumour burden correlate with high marker values 
(Bast et al., 2001; Berruti et al., 1994).Metastatic disease, especially in the liver, bones and 
lungs, and metastatic pleural effusions, can give rise to pathological CA 15.3 values 
(Tampellini et al., 1997). Imaging modalities are important not only for seeing tumour 
lesions in the case of cancer , but also in evaluating the size of the tumour for staging and 
restaging assessment, in monitoring the therapy responses, and during follow-up (Ugrinska 
et al., 2002). The link between imaging and CA 15.3 can be found in the report by Tampellini 
et al. (Tampellini et al., 1997). The authors demonstrate that the supranormal value of CA 
15.3 was positive more frequently in patients with liver metastases (74.6%), pleural effusion 
(75.7%), and oestrogen receptor (ER)-positive tumours, and in patients with a larger extent 
of the disease than in patient subgroups with recurrence in the bones (65%), lungs (61.8%) or 
soft tissue (47.1%). At multivariable logistic regression, the pleural effusion, ER status and 
disease extent were confirmed as independent variables in determining CA 15.3 positivity. 
Considering overall survival as the end-point, the multivariable survival analysis calculated 
with the COX regression model showed that ER status, disease extent and liver metastases 
were independent variables, and when the disease extent variable was removed, the CA 15.3 
values became an independent variable associated with poor prognosis (Tampellini et al., 
1997). Thus the extent of the disease represents a marker of poor prognosis, and the use of 
an imaging tool allows it to be assessed; however if this is not possible, tumour marker 
values can be used. An asymptomatic patient with elevated tumour markers is quite 
common in daily practice. Elevated tumour marker levels (both CEA and CA 15.3) are 
associated with an increased risk of recurrence (Nakamura et al., 2005), but localization of 
metastases or recurrent disease remains a challenge, which often requires an extensive 
diagnostic workup. The management of cancer patients has improved in the last few 
decades with the introduction of 18F-FDG PET (Zangheri et al., 2004). Tumour cells have an 
increased metabolism of glucose (Warburg et al. 1931), which has been shown to be true for 
breast cancer cells (Adler et al., 1993; Wahl et al., 1991; Nieweg et al., 1993; Avril et al., 2001). 
Glucose metabolism can be imaged by metabolic diagnostic modality, such as FDG PET. The 
imaging tool permits a complete tumour staging with a single whole-body investigation, 
even allowing the diagnosis of a significant number of metastases, which would be missed 
or incorrectly diagnosed by computed tomography (CT), magnetic resonance imaging (MRI) 
and bone scintigraphy. This indicates that a whole-body PET can be fundamental in the 
search for metastasis, especially when recurrences are suspected due to a progressive 
increase in circulating tumour markers (Hoh et al., 1999). Circulating tumour markers are 
biochemical products of the same alterations imaged by nuclear medicine (such as the 
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overexpression and production of tumour-associated antigens on the membrane surface and 
in the bloodstream), or, alternatively, resulting from completely different pathways. 
Recent data suggests that FDG PET is a useful technique for detecting recurrent breast 
cancer suspected on the basis of an asymptomatically elevated tumour marker level and 
negative conventional imaging results (Siggenkolw et al., 2004; Liu et al., 2002). In the last 
few years, PET/CT, as an integrated instrument for the evaluation of suspected disease 
relapse for various tumours (e.g. lymphomas), has become routinely used, showing to be 
superior to PET alone in re-staging the disease in patients who have been previously treated, 
particularly when the only indicator of recurrence is a rise in serum tumour markers (such 
as CA 15.3) (Suarez et al., 2002; Flamen et al., 2001). At present, as described by Siggelkow et 
al. (Siggelkow et al., 2004), PET should only be performed in cases where tumour marker is 
increasing and conventional imaging is unclear. In Figure 1 are shown two examples of PET 
and PET/CT scan in breast cancer patients. 
 
Fig. 1. Left: coronal images of PET scan. Right: PET/CT images on the three planes 
(transverse, sagittal and coronal)  
4. A summary of articles concerning PET and PET/CT in patients with rising 
tumour markers 
Elevated levels of tumour markers are frequently registered in the follow-up of breast 
cancer patients. This presents a diagnostic challenge, often requiring some conventional 
diagnostic tests to localize the metastases or recurrent disease. Cases of asymptomatic 
patients with elevated tumour marker levels have demonstrated a high rate of false-
negatives with conventional morphological imaging modalities (Haug et al., 2007). In a 
review by Lamy et al. (Lamy et al., 2005), the authors summarized the results of a set of 
some studies in colorectal, breast and ovarian cancer. They stressed that one of the major 
indications of tumour marker is the detection of occult disease; less than 20% of tumour 
marker elevations are associated with clinical and radiological findings. Such elevations 
have led the medical community to doubt the value of tumour marker-based follow-up, 
such as CA 15.3 in breast cancer. PET with FDG using metabolic parameters of malignant 
cells allows tumour recurrences to be seen at the early stages of development, before any 
morphologic changes can be seen by radiological examinations. The authors  underlined 
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that, given the early positives they find, and that they are non-invasive and cost-effective, 
tumour markers have become an invaluable guide to the prescription of 18F-FDG PET in 
oncology, giving a ‘map’ of widespread disease. Suarez et al (Suarez et al., 2002) reported 
that values of CA 15.3 above 60 UI/ml were always associated with positive PET results and 
values below 50 UI/ml were accompanied by negative PET results. In the interval from 50 to 
60 UI/ml the PET could be either positive or negative. Symptomatic patients, or those with 
suspected disease relapse, despite negative markers or both negative markers and CT, can 
nevertheless present with disease recurrence. Some authors have proposed that whole-body 
PET may become the method of choice for the assessment of asymptomatic patients with 
elevated tumour marker levels (Ugrinska et al., 2002; Siggelkow et al., 2004; Trampal et al., 
2000). Shen et al. (Shen et al., 2003) screened 1283 patients who underwent whole-body FDG 
PET studies with the additional help of the serum levels of tumour markers. The final 
diagnoses were obtained by other imaging modalities of pathological findings. The authors 
concluded that the whole-body FDG PET, with the additional help of tumour markers, 
could reduce false negative and false positive results of FDG PET in all types of cancer.  
In detail, we will consider an accurate description of various reports published concerning 
the employment of PET or PET/CT in the detection of breast cancer recurrence based on 
tumour marker levels, making some observations. 
4.1 Tumour markers and PET alone 
Lonneaux et al. (Lonneaux et al., 2000) were the first authors to evaluate the place of whole-
body FDG PET in women presenting symptoms of recurrence, with a special focus on 
patients with an isolated increase in tumour markers. They studied 39 patients, 34 of whom 
were selected due to their increase in tumour markers. They found an overall sensitivity of 
94%, specificity of 50%, NPV of 60%, PPV of 91% and accuracy of 87%. The high accuracy 
was related to the discovery of recurrence in 37 out of 39 patients (two false negative 
diseases were due to lymphedema of the arm and carcinomatosis that developed after some 
months). They demonstrated that FDG PET is useful in the evaluation of women suspected 
of a distant recurrence of breast cancer. PET allows for an earlier diagnosis of recurrence, 
which can lead to earlier therapy. As far as patient management is concerned, their results 
suggest that, as it is a non-invasive and highly sensitive imaging procedure, whole-body 
PET FDG should be performed as first line imaging when a recurrence of breast cancer is 
suspected on the basis of clinical symptoms or biological signs. In the second place, and only 
when patient management could be affected, dedicated and oriented CT or MRI could 
confirm precisely the anatomical localization of the sites with increased FDG uptake. Indeed 
there is no need for additional imaging procedures if PET shows disseminated bone disease 
or multiple lymph node metastases. On the contrary, the cases of equivocal PET findings 
should be checked by appropriate procedures. 
Trampal et al. (Trampal et al., 2000) studied 72 patients with different types of cancer, 23 of 
whom had breast cancer. FDG PET detected lesions in 85% of the patients, and at the end of 
the study this was confirmed for 33 of the patients. PET sensitivity and specificity were 
96.4% and 75.6%, respectively. They concluded that PET was an accurate tool in the 
diagnosis of recurrent tumoural disease in patients with rising tumour marker levels and 
negative conventional imaging, which could change the form of therapeutic management.  
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Pecking et al. (Pecking et al., 2000) reported that 1) blood tumour marker are widely used in 
the follow-up of patients treated for a malignant tumour and 2) in many cases where the 
tumour associated marker increases, the clinical and radiological evaluations remain 
normal. FDG PET and CT-scan have proven to be powerful tools in oncology, and their use 
in such situations may give a new appraisal on the development of the disease. They tested 
70 patients with isolated increasing in tumour markers (CEA, CA 19.9, CA 15.3, CA 125). 
Focusing on breast cancer and CA 15.3, as well as ovarian cancers and CA 125, the 
sensitivity and predictive value reached 100%. Patients exhibiting a tumour target 
associated with an increase in blood tumour markers can be treated earlier with dedicated 
protocols. They concluded that where occult metastasis is detected by blood marker 
measurements, the tumour volume is smaller than when the patient presents overt 
symptoms; the treatment should therefore be more effective, and the use of imaging is 
advised. The same authors, after one year, (Peching et al., 2001) evaluated the efficacy of 
PET in clinically disease-free breast cancer patients in whom occult disease was suspected 
on the basis of increased blood tumour markers. They studied 132 patients who had 
received a totally negative follow-up evaluation, but who had a persistent increase in blood 
CA 15.3 confirmed by serial measurements. The confirmation of disease relapse was given 
by fine needle biopsy or surgical biopsy no later than two months later, or by imaging 
follow-up performed 6-12 months later. Ninety-two out of 119 eligible patients had a 
recurrence of disease after two months, while 102 out of 119 had a recurrence after 12 
months, thus the sensitivity of PET/CT was 92.9% and 93.6%, respectively. The increase 
between the early and delayed recurrence of disease was more evident for specificity and 
PPV (30 vs. 60% and 86.8 vs. 96.2%) than accuracy (83.2 vs. 90.7%) and NPV (46.1 vs. 46.1%). 
Moreover, PPVs of PET increased with the serum CA 15.3 levels (diagnostic accuracy after 
12 mo. was CA 15.3 <30 and ≤50 U/ml = 84.0% vs. serum CA 15.3 > 75 U/ml = 90.3%). They 
concluded that when rising serum CA 15.3 is confirmed, positive FDG imaging can be 
significantly associated with recurrence, becoming significantly associated to recurrence or 
metastatic disease within one year (p=0.036 for 12 mo. vs. 0.046 for 2 mo.). Moreover, they 
suggested designing new therapeutic protocols based on positive FDG imaging in disease-
free patients with an elevated serum CA 15.3 marker.  
Spanish authors (Suarez et al., 2002) retrospectively studied 45 women with a histological 
diagnosis of breast cancer who had undergone a tumour marker-guided whole-body FDG 
PET. All patients were in remission, and without any other clinical symptoms or 
instrumental signs  of relapse, except for the progressive elevation of CA 15.3 and/or CEA, 
tested during follow-up. FDG PET was obtained in 38 out of 45 patients, with 24 true-
positives and 3 false positives. In total, 54 sites of FDG accumulation were revealed and 48 
out of 54 patients were confirmed as metastases. The performances of tumour marker-
guided FDG PET per patient were as follows: sensitivity = 92%, specificity = 78%, PPV = 
89%, NPV = 82%, accuracy = 89%. They concluded that tumour marker-guided PET in the 
follow-up of breast cancer patients is of clinical utility. PET/CT was also able to identify 
three new neoplasms (ovary, contralateral breast and endometrium cancers). The inclusion 
of PET in the diagnostic algorithm allowed the clinical management to be modified (the 
change was shown in 24 out of 38 patients, or 63%) in those patients in whom a tumour 
relapse or unexpected primary neoplasm was discovered. It should be noted that tumour 
marker-guided PET led oncologists to adequate therapeutic decisions - performing different 
treatments - when three unknown primary cancers were detected.  
www.intechopen.com
Tumour Markers and Molecular Imaging with FDG PET/CT  
in Breast Cancer: Their Combination for Improving the Prediction of Disease Relapse 
 
299 
Liu et al. (Liu et al., 2002) studied 30 patients with recurrent breast cancer after primary 
treatment. They evaluated both CA 15.3 and CEA, dosing the same day as FDG PET. They 
used the threshold of 32 UI/mL and 5 UI/mL respectively for CA 15.3 and CEA, useful to 
address PET. Employing this cut-off value, they found that PET had a high sensitivity and 
specificity (96 and 90%, respectively), identifying the presence of disease in 25 out of 28 
recurrent patients, with only one false-negative result and two false positives. Their 
conclusion was that FDG PET is a useful technique for detecting recurrent breast cancer 
suspected from asymptomatically elevated tumour marker levels and negative or equivocal 
other imaging modality results. 
Galloswitch et al. (Gallonswitch et al., 2003) studied 62 patients with breast cancer who were 
evaluated with both conventional imaging and FDG PET for disease relapse. A patient-
based and lesion-based analysis was performed. The concordance of the conventional 
imaging and FDG PET were computed. Furthermore, patients were divided in two groups 
(with negative and positive tumour markers; CA 15.3 and CEA). PET in both subsets of 
patients showed a higher diagnostic accuracy than conventional imaging (87 vs. 90.3% and 
61.5 vs. 90.3% respectively in patients with pathologic and normal tumour markers). They 
concluded that 18F-FDG PET demonstrates apparent advantages in the diagnosis of 
metastases in patients with breast cancer compared with conventional imaging on a patient 
base. On a lesion base, significantly more lymph nodes and fewer bone metastases can be 
detected using 18F-FDG PET compared with conventional imaging, including bone scan. 
Concerning bone metastases, sclerotic lesions are predominantly detected by bone scan. On 
the other hand, there are several patients with more FDG positive bone lesions and also 
mixed FDG positive/Tc-99m MDP negative and FDG negative/Tc-99m MDP positive 
metastases. In patients with clinically-suspicious, but negative, tumour marker profiles, 
FDG PET seems to be a reliable imaging tool for the detection of tumour recurrence or 
metastases.  
Kamel et al. (Kamel et al., 2003) studied 43 breast cancer patients with suspected disease 
relapse. Twenty-five  of those patients had available value of tumour markers that had been 
collected within two weeks of their PET scan. Among the 25 patients, 19 were proven to 
have disease relapse, while six patients were categorized as being free from any tumour-
related manifestation. Eight patients with local recurrence (n=3), distant metastases (n=1), or 
both (n=4) did not show elevated values (an average of 12.4 U/ml) despite the true positive 
PET findings. However, in 11 patients both PET findings and tumour marker status (median 
42 U/ml) indicated disease recurrence. Three of these 11 patients had characteristically 
increased value of CA 15.3 (1394 U/ml, 666 U/ml, 185 U/ml), and PET revealed extensive 
disease relapse, while four had normal tumour markers (an average of 16.6) and two had 
slightly elevated values (an average of 21.5 U/ml). FDG PET was more sensitive than serum 
marker CA 15.3 in detecting relapsed breast cancer, CA 15.3 levels were normal in eight out 
19 (42%) patients with true positive PET findings. 
Siggelkow et al., (Siggelkow et al., 2003) studied 35 patients suspected of having recurrent 
disease or elevated tumour markers. Depending on the region of suspicion, conventional 
imaging included chest X-ray, MRI, CT and US. All patients had had at least 12 months of 
follow-up treatment. In the patients who were examined due to elevated CA 15.3, PET was 
able to detect recurrence or metastatic disease in six of the eight patients (sensitivity = 75%). 
PET missed three tumour sites in three patients: two supraclavicular lymph node metastases 
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and one lung metastasis. The overall sensitivity and specificity for PET for the whole series of 
patients was 80.6% and 97.6%, respectively. The same authors (Siggelkow et al. 2004) declared 
in a review that few studies have gathered sufficient data on the value of FDG PET in a patient 
with asymptomatically elevated tumour marker levels during follow-up for breast cancer.  
Eubank et al. (Eubank et al., 2004) retrospectively analysed 125 consecutive patients with 
breast cancer with the aim of 1) evaluating the impact of FDG PET on defining the extent of 
disease and 2) evaluating the impact of FDG PET on patient management. The patients were 
referred for FDG PET for the following reasons: evaluation of disease response or viability 
after therapy (n=43; 35%), local recurrence with intent of aggressive local treatment (n=39; 
31%), equivocal findings on conventional imaging (n=25; 20%), evaluation of the extent of 
the disease in patients with known metastases (n=13; 10%) and elevated tumour markers 
with unknown disease site (n=5; 4%). In this latter subset of patients, the authors found that 
PET enabled the therapeutic management to be changed in three out of five patients (60%); 
in particular, one patient received systemic therapy other than surgery (intermodality 
change) and two patients were treated with systemic chemotherapy (intramodality change). 
For the whole group, the overall sensitivity, specificity, and accuracy of FDG PET was 94%, 
91% and 92%, respectively. The final conclusions of the study were: 1) FDG PET helped to 
define the extent of disease and determine the treatment plan in a significant number of 
patients with advanced breast cancer; 2) the treatment plan was altered by FDG PET 
findings most frequently in patients who had loco-regional recurrence and an increase in 
tumour markers. 
The findings of the articles mentioned above are summarized in Table 2: 
 
Study 
No. of patients/ 
proven recurrence 
Sensitivity (%) Specificity (%) 
Lonneux et al., 2000 33/31 - - 
Pecking et al., 2000 132/92 93.6 - 
Liu et al., 2002 30/28 96 90 
Suarez et al., 2002 38/27 92 75 
Kamel et al., 2003 25/19 - - 
Table 2. A summary of current studies on the impact of FDGPET in patients with elevated 
tumour marker levels 
Current  reports univocally indicate that the use of FDG PET is rational in patients with 
asymptomatically elevated tumour marker levels and equivocal findings on conventional 
imaging. Both FDG PET and tumour marker status are biological tools that characterize the 
functional state of existing tumour tissue, but the tumour marker status was previously 
reported to be too insensitive to identify the existence of tumour tissue with a relatively 
smaller burden (Kokko et al., 2002). However, FDG PET is not sensitive enough for the 
detection of micrometastases, yet it remains the most accurate imaging device for early 
breast cancer recurrence detection. In fact, although FDG PET cannot rule out microscopic 
disease, it nevertheless has particular value in providing a reliable assessment of the true 
extent of the disease in a single examination (Vranjesevic et al., 2002; Haug et al., 2007).  
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4.2 PET vs. PET/CT and tumour markers 
A PET scan alone has certain limitations, for example the exact localization of 
pathologically-increased focal glucose metabolism can be crucial, and physiological 
accumulation of FDG without precise anatomical localization can be misinterpreted as 
pathological. Conversely, CT permits exact anatomical localization of small physiological 
and pathological foci, but does not provide any information with regard to tissue 
metabolism. Combining both morphological and functional imaging technologies in a single 
scanner can be expected to overcome the respective limitations of CT, MRI, and PET, and 
provide the additional advantage of simultaneous data acquisition, obviating the need for 
patient repositioning, and so on. Haug et al. (Haug et al., 2007) studied patients with an 
isolated increase of tumour markers, who were asymptomatic but with suspected disease 
recurrence. Thirty-four patients were studied, five of whom were symptomatic and 29 
asymptomatic. The authors compared PET, CT and PET/CT in a subset of patients with 
high levels of tumour markers (both CEA and CA 15.3), showing that the combined 
modality is associated with a higher diagnostic accuracy than when considered alone. 
PET/CT was able to identify 149 malignant foci in 24 patients (71%); CT identified 96 foci 
and PET 124 foci, in 18 and 17 patients respectively. The PET results were no different to the 
CT results, but both were significantly different from the PET/CT results (all p<0.01) (see 
Table 3). 
 
 Sensitivity (%) Specificity (%) 
PET 88 78 
CT 96 78 
PET/CT 96 89 
Table 3. Diagnostic accuracy of PET alone, CT alone and PET/CT  
The authors concluded that PET/CT is a valuable modality for the follow-up of patients 
with suspected breast cancer relapse and elevated levels of tumour markers.  
4.3 PET/CT and tumour markers 
Fueger et al. (Fueger et al., 2005) made a comparison between PET and PET/CT for 
diagnostic accuracy and the advantages for patients with a recurrence of breast cancer. They 
studied 58 patients with suspected disease recurrence, including the elevation of tumour 
marker levels (21/58 patients). They suggested that integrated PET/CT restages breast 
cancer patients with a higher accuracy than PET alone, but only marginally (p=0.059). This 
observation emphasizes the need for a careful evaluation of the entire CT data set for an 
appropriate interpretation of PET/CT studies. 
Saad et al. (Saad et al., 2005) in their retrospective study evaluated 35 patients with 
metastatic breast cancer. The results of PET/CT were compared with CA 27.29 and 
circulating tumour cells (CTC). A correlation between the results of PET/CT scans, CA 27.29 
and CTC was found. CA 27.29 and CTC had poor sensitivity (59 and 55%, respectively) and 
NPV (24 and 33%, respectively) to detect metastatic disease observed on PET/CT scan, 
therefore PET remains the most sensitive test in detecting metastatic disease. 
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Radan et al. (Radan et al., 2006) retrospectively evaluated 47 patients with elevated tumour 
markers, 1 - 21 years from diagnosis. Thirty patients had had a recurrence of disease and 16 
had not. Sensitivity, specificity and accuracy were 90%, 71% and 83%, respectively. PET/CT 
was compared to contrast enhancement CT demonstrating a higher sensitivity (85 vs. 70%), 
specificity (76 vs. 47%) and accuracy (81 vs. 59%). The impact of PET/CT on management 
was found in 51% of the patients. In conclusion, PET/CT had high performance indices and 
was superior to CT for the diagnosis of tumour recurrence in patients with breast cancer and 
rising tumour markers. 
An Italian group (Grassetto et al., 2010) retrospectively studied 89 breast cancer patients 
with high values of CA 15.3 and inconclusive or negative PET/CT findings. Forty out of 89 
patients (45%) had evidence of disease at FDG PET/CT, 23 had a solitary FDG-positive 
small lesion multiple cancer deposits were found in 14 of the 23 patients, and three patients 
were negative. The authors found that PET/CT may be able to detect occult metastatic and 
recurrent disease in post-therapy breast cancer patients with rising CA 15.3 levels and 
negative conventional imaging. They suggested that it could be reasonable to use tumour 
markers for guiding the performance of PET with the purpose of identifying the site of 
relapse in order to choose the most appropriate treatment.   
Filippi et al. (Filippi et al., 2011) evaluated the role of FDG PET/CT in recurrent breast 
cancer detection in the presence of high levels of tumour markers and equivocal or negative 
conventional imaging. They studied 46 patients without any other clinical or laboratorial 
sign of disease; conventional imaging was negative in 29 patients and inconclusive in 17. 
FDG PET/CT resulted positive in 34 out of 46 patients. True-positive findings were found in 
33 out of 46 patients (sensitivity = 86.8%, PPV = 97.1%) while false-positive and false-
negative results were shown in six patients (specificity = 87.5%, NPV = 58.3%). The global 
diagnostic accuracy of PET/CT for disease detection was 86.9%. Change in clinical 
management was obtained in 50% of cases (23 out of 46), performing selective therapy in a 
number of patients. They concluded that the FDG PET/CT scan plays an important role in 
restaging breast cancer patients with rising tumour markers and negative or equivocal 
findings in conventional imaging techniques, with a consequent significant clinical impact 
on further management in these patients.  
Champion et al. (Champion et al., 2011) studied 368 patients, 228 of whom had increased 
CA 15.3 and/or CEA. The cut-off value of CA 15.3 serum level was 60 UI/mL, as previously 
defined by various studies (Suarez et al., 2002; and Aide et al., 2007; Molina et al., 2005). The 
average CA 15.3 serum level was significantly higher in the true positive group than in the 
false negative one (166±115 vs. 77±52 UI/mL; p<0.001) and the true-negative one (166±115 
vs. 65±56 UI/mL; p<0.001) (Figure 2). In asymptomatic patients with rising tumour markers, 
FDG PET/CT imaging is an accurate modality to screen for breast cancer recurrence. It is 
more sensitive than a conventional imaging workup;  showing the extent of disease, it 
enables further treatment to be adjusted, proving a general picture in a high performance 
“one stop-shop” procedure.   
In a study performed at our Nuclear Medicine Unit (Evangelista et al., 2011), we assessed 
the role of tumour markers, CT and 18F-FDG PET/CT in identifying disease relapse in 
patients with breast cancer which had already been treated, and the impact of PET/CT 
findings on patient management. We studied 111 patients with breast cancer with clinical-
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biochemical signs of loco-regional and distant recurrence of disease. Within three months, 
all patients performed CA 15.3, CT and PET/CT imaging for the evaluation of the extent of 
the disease. Recurrence was found in 32 out of the 111 patients, and PET/CT recognized the 
majority of patients with disease relapse, irrespective of the value of CA 15.3 and CT 
findings, identifying 81% of cancer recurrence and missing only 19%, with a gain of 30% 
toward tumour markers and 10% toward CT (see Table 3). The change in management was 
significantly important after PET/CT evaluation (change in 56% vs. 34%, respectively for 
PET/CT and CA 15.3). Furthermore, no advantage was obtained by reducing the value of 
the abnormal cut-off point of CA 15.3 from 31.0 to 19.1 U/mL, increasing the detection of 
recurrence by only 6%. 
 
Fig. 2. A histogram showing the different groups of PET/CT results expressed as the number 
of patients against the CA 15-3 blood level (cut-off, 60 UI/mL) (from Champion et al., 2011). 
 
 Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Accuracy 
(%) 
Tumour markers 50 69 40 77 64 
CT 72 37 32 76 47 
PET/CT 81 62 41 87 60 
Elevated tumour markers
CT 69 93 50 72 60 
PET/CT 88 33 47 80 55 
Normal tumour markers
CT 75 29 24 80 39 
PET/CT 75 60 35 89 63 
PPV, positive predictive value; NPV, negative predictive value 
Table 3. Diagnostic accuracy of tumour marker (CA 15.3), CT and PET/CT in detecting 
relapse of disease 
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There is a general consensus in literature that steadily rising levels of CEA and CA 15.3 
value must be regarded as a significant sign of change in tumour cell growth; this means 
that tumour marker determination during follow-up in breast cancer patients who have 
been radically operated on could anticipate the clinical diagnosis of cancer relapse. In our 
opinion, the use of PET/CT in patients with breast cancer could improve accuracy in the 
determination of the extent of the disease in case of an increase of tumour markers, but it is 
important to evaluate the trend of the increase in tumour marker rather than its single value. 
In fact, several non-cancerous conditions (benign breast or ovarian disease, endometriosis, 
pelvic inflammatory disease and hepatitis) can raise levels of CA 15.3, thus reducing the 
specificity of biochemical relapse; on the contrary, PET/CT can identify the disease before it 
becomes clinically manifested, even  when the value of tumour markers is in a normal 
range.  
5. Doubling timing and serial determinations 
A discrepancy exists between the high positivity rate of serological markers in metastatic 
disease vs. the low positivity rate of serological markers in metastatic disease and the low 
positivity rate related to early relapse, when the results of tumour marker assays are 
interpreted by means of a dichotomous positive/negative cut-off point. This latter criteria, 
although easy to use and well accepted in clinical practice, is not powerful enough for the 
detection of early biological relapse: a relevant quantity of tumour tissue is necessary to produce a 
sufficient quantity of tumour markers to exceed the cut-off point. Dynamic interpretation based on 
serial samples might provide earlier diagnostic information, so a significant increase could 
be detected before exceeding the cut-off level, i.e. the difference between the values in three 
consecutive determinations should be at least two fold the inter-assay coefficient of variation 
(20%). The interval between the serial tests should be at least one month.  
Mariani et al. (Mariani et al., 2009) recommended that the tumour markers should be 
considered as an indicator of disease presence, not only a tumour marker value above the 
normal limit (dichotomic criteria) but also a difference between two consecutive 
measurements greater than a critical value (dynamic criteria). Serial CA 15.3 measurements 
may be an efficient and cost-effective method of monitoring disease progression, and this is a 
potentially powerful means of obtaining information about breast cancer whilst causing 
minimal morbidity, inconvenience and cost (Buffaz et al., 1999). Both CA 15.3 and PET are 
based on metabolic changes due to tumour activity; they provide information on disease 
progression in a different way to conventional imaging. The advantage of adding PET or 
PET/CT in combination with constant elevation of CA 15.3 (15) could be translated into a 
more valuable method of identifying earlier metabolic changes (which is the basis of the PET 
principle) even before the morphological changes (noticeable with ultrasound and CT) occur. 
Aide et al. (Aide et al., 2007) retrospectively evaluated 35 FDG PET examinations in 32 
patients with CA 15.3 blood level above the normal range, and negative conventional 
imaging within three months before a PET exam. CA 15.3 assays were performed prior to 
the PET examinations and, all using the same techniques, were collected and used for 
doubling time calculation if 1) no therapeutic modification occurred in the meantime, and 2) 
the delay between assays was less than six months. Median CA 15.3 blood levels were 
higher in the positive PET group (100 U/ml) than in the negative group (65 U/ml) (p=0.04). 
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The likelihood of depicting recurrence was higher in patients with a short doubling time 
(<180 days) (p=0.05), a CA 15.3 blood level >60 U/ml (p=0.05), and when a short doubling 
time was associated with a CA 15.3 blood level >60 U/ml (p=0.03). The authors concluded 
that the likelihood of recurrence was influenced by CA 15.3 blood level and doubling time. 
In our recent report (Evangelista et al., 2011) we assessed the relationship between serial 
measures of CA 15.3 and FDG PET/CT findings in the follow-up of patients who had 
already been treated for breast cancer. In sixty patients, three serial measures of CA 15.3 
were collected within one year of the PET/CT examination. Coefficient of variation of the 
CA 15.3 serial determinations was significantly higher in patients with positive than 
negative PET/CT (39 vs. 24%, p < 0.05). ROC analyses showed that an increase of CA 15.3 
between the second and third measures have better individuated positive PET/CT and 
disease relapse (AUC 0.65 and 0.64, respectively; p < 0.05). We concluded that an increase of 
CA 15.3 could be considered optimal in addressing FDG PET/CT examination during breast 
cancer patients’ follow-up. PET/CT performed just on time might allow disease relapse in 
breast cancer patients to be detected earlier and with higher diagnostic accuracy. 
6. The current recommendations according to the American and European 
societies  
Approximately 30-50% of breast cancer patients have a recurrence of disease within ten 
years after diagnosis. Several international guidelines help physicians using tumour 
markers to give practical recommendations for the appropriate interpretation of 
circulating tumour markers. Due to low levels of evidence; the ASCO recommendations 
for the use of tumour markers do not support the determination of CA 15.3 during the 
follow-up of patients who have been treated for breast cancer, for monitoring the 
recurrence of disease (Harris et al., 2007). In clinical practice, disease relapse is suspected 
if there is positive clinical findings, the appearance of new lesions on imaging 
examinations, and/or unclear and persistent elevation of tumour markers. The 
“biochemical evidence” of a possible cancer relapse suggested by increased tumour 
markers leads oncologists to discover or exclude the sites of the cancer lesions through 
conventional radiological imaging techniques or nuclear medicine modalities (Strauss et 
al., 1991; Brown et al., 1996). The early individuation of disease relapse could improve the 
prognosis and allow for better management, through starting a new treatment or 
changing the ongoing therapy. Currently, according to ASCO guidelines (Khatcheressian 
et al., 2006), the follow-up of breast cancer patients should involve only physical 
examination and conventional mammography; whereas in the presence of new symptoms 
oncologists recommend performing conventional imaging, such as a chest-X ray, CT or 
MRI and PET scan. The European Group on Tumour Marker (EGTM) (Molina et al., 2005) 
panel suggests the following approach during the follow-up of asymptomatic women: 
tumour markers should be determined every two - four months (according to the risk of 
recurrence) during the initial five years after diagnosis, and at yearly intervals thereafter. 
This practice could be considered to be the most useful for monitoring disease 
development and reducing the lead time. 
PET is a rapidly evolving field at both national and international level, with sometimes 
striking differences between its use in individual countries (Boellaard et al., 2009). The 
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indications for PET and PET/CT are constantly changing, and require updating over time. 
Based on the current recommendations by the European Association of Nuclear Medicine 
(EANM guidelines), other than staging and restaging by PET/CT, establishing and 
localizing disease sites as a cause for elevated serum markers in some tumours (e.g. 
colorectal, thyroid, ovarian, cervix, melanoma, breast and germ–cell tumour) are also 
considered important aims.  
7. Discussion 
There are several patients in whom tumour marker levels are either high or progressively 
increasing, and neither physical examination nor diagnostic imaging are able to detect the 
tumour. In these cases the level of tumour markers (biochemical occult disease) serves as a 
guide to studying the patient with more powerful instruments (tumour marker-guided 
imaging) (Figure 3).  
 
 
 
Fig. 3. The impact of technical implementation of diagnostic imaging (from Prof. 
Bombardieri Emilio, 1stImmunometry Congress ; 27 March 2009, Bari, Italy) 
As previously mentioned, PET and PET/CT have proven to be useful imaging devices for 
earlier detection of disease recurrence, especially when tumour markers are increasing.  
The main question is: when is the association of tumour markers and PET or PET/CT 
(tumour marker-guided imaging)  useful? It is undoubtedly useful at early presentation for 
patients at high risk of metastases, in the diagnosis of tumour relapse/restaging, and for 
monitoring tumour response (Prof. Bombardieri Emilio, 1st Immunometry Congress ; 27 
March 2009, Bari, Italy). In Table 4 the advantages and limitations of tumour markers as a 
guide for PET/CT imaging are summarized: 
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Added value Limitations 
Diagnosis of metastases at 
tumour presentation  
PET seems more accurate 
than conventional 
imaging in the diagnosis 
of metastases at cancer 
presentation  
(in particular for internal 
chain lymph nodes). 
PET usefulness is related to 
the stage of disease, being 
more accurate for stage II-III. 
The sensitivity of tumour 
markers is very low at early 
stages. tumour markers tests 
are not recommended at 
tumour presentation in low-
risk patients. 
Detection of recurrent 
Disease 
Limited sensitivity of 
PET and tumour markers 
in depiction of loco-
regional recurrences 
High accuracy (~90%) for 
the detection of 
metastatic disease. 
Inadequate detection by PET 
of anatomical details. 
PET/CT overcomes this 
problem and increases the 
diagnostic accuracy (with a 
gain of ~ 10% in diagnostic 
accuracy, Haug et al., 2007). 
Unclear elevation of tumour 
markers in asymptomatic 
patients during follow-up 
High sensitivity (> 90%) 
for the detection of occult 
recurrence in 
asymptomatic patients 
with a progressive 
increase of tumour 
markers levels. 
Some false negative results 
in breast cancer with low 
metabolism (lobular 
carcinoma). Additional 
conventional imaging is 
sometimes necessary. 
Table 4. A summary of the advantages and limitations of tumour markers as a guide for 
PET/CT imaging (from Prof. Bombardieri Emilio, 1stImmunometry Congress ; 27 March 
2009, Bari, Italy) 
Tumour marker tests are a metabolic measure of tumour growth and tumour activity, and 
well integrate the metabolic imaging information. The association of tumour marker with 
PET/CT appears to be perfect giving qualitative and quantitative metabolic information, in 
particular tumour marker concentrations express the blood measure of the tumour 
products, and the pixel content of morphologic images is related to tumour uptake.  
7.1 Considerations 
1. In the majority of reports analysed, tumour marker-guided PET and PET/CT have 
shown a high diagnostic accuracy in the early detection of breast cancer recurrence; 
2. PET and PET/CT can be considered to be accurate and powerful tools in detecting 
disease recurrence even when tumour markers are low or in a normal range; 
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3. The association of tumour markers and PET/CT also has an impact on patient 
management; many reports have described a change in planned therapy of about 
50%. In a review, Yu et al. (Yu et al. 2007) discussed cancer biomarker development, 
opportunities for PET to elucidate tumour biology, and the potential role of PET in 
clinical research and practice. They underlined that the practice of oncology has been 
changing, with novel biologic agents broadening the therapeutic armamentarium. 
The concept of individualized cancer care, where therapies are selected based on the 
unique characteristics of the patient’s tumour, is gaining favour as an approach to 
address the heterogeneity of cancer; for this reason they were incited to discover 
biomarkers with prognostic and predictive value to improve drug selection, 
alteration and cancer development. For this purpose, the combination of metabolic 
data and molecular imaging with PET or PET/CT is at the forefront of this critical 
field.  
8. Conclusions 
Tumour marker-guided PET during the follow-up of patients who have already been 
treated for cancer has not yet been investigated sufficiently. The questions to be solved are: 
1) Can the combination of tumour markers and PET scans substitute all other conventional 
modalities currently used in follow-up? 2) Can this approach affect the survival of patients? 
Considering the need for stricter integration between laboratory tests and metabolic 
imaging, in particular FDG PET, we will hopefully be able to answer these questions in the 
near future.  
However, the use of CA 15.3 tests in breast cancer follow-up could involve a considerable 
risk of over-diagnosis and lead time. When the test result is positive but there is no other 
confirmation of metastatic disease, decision-making is difficult as to whether to treat or not 
(Kokko et al., 2002).  
As documented in the “Recommended Breast Cancer Surveillance Guidelines” adopted by 
ASCO, the achievement of survival benefit with clinical follow-up is one of the most 
important documents that did not confirm the necessary of more aggressive follow-up 
strategies (Levels of evidence). However, the majority of the studies were carried out 10-20 
years ago when many of the current drug regimens were not available. The Association of 
Breast Surgery to The British Association of Surgical Oncology has noted the above report 
and made a number of recommendations. One of the most important recommendations 
states that “follow-up should be stratified according to disease risk”. The follow-up 
management of breast cancer patients based on different risk category of recurrence should 
therefore be appropriately defined. We suggest considering three categories of patients: 
1. Low risk of recurrence (ductal carcinoma in situ, DCIS; lobular carcinoma in situ, LCIS) 
2. Intermediate risk (hormone receptor positive cancer; invasive ductal cancer, IDC; 
invasive lobular cancer; HER-2 negative cancer) 
3. High risk (triple negative, advanced stage at diagnosis, cancer associated with familiar 
genetic mutations, and any remaining categories) 
Figure 4 shows a possible clinical and diagnostic algorithm during follow-up: 
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BC = breast cancer 
Fig. 4. A follow-up algorithm in breast cancer patients based on risk category (*low-risk and 
**high risk breast cancer patients are referred to the above definitions) 
The clinical experience in breast cancer management and different studies support the 
following concepts: a) a tumour marker test is not useful in the diagnosis of primary breast 
cancer, due to their very low sensitivity at cancer presentation; b) there is a correlation 
between CA 15.3 levels and the presence of bone and visceral metastases; c) the combination 
of tumour markers with diagnostic imaging can improve the diagnostic sensitivity and the 
PPV; d) tumour markers may be helpful in the interpretation of equivocal bone scans or any 
other equivocal imaging modality; e) bone scintigraphy cannot be precluded on the basis of 
normal tumour marker tests in the presence of suspicious skeletal metastases alone; f) some 
bone metabolic markers might be helpful in the evaluation of “flare phenomenon” and 
monitoring therapy response; g) even if tumour marker-guided PET still has to be 
extensively evaluated, the current experience demonstrates the potential of FDG-PET in 
discovering occult soft and bone metastases in the presence of a progressive increase of 
serum tumour markers (Ugrinska et al., 2002).   
Some limitations of this article should be remembered: 1) many of the revised articles were 
retrospective; 2) we reported studies which considered both patients who underwent FDG 
PET alone and PET/CT imaging for increase in tumour markers, 3) the imaged field of view 
for whole-body PET/CT protocols is not already standardized and varies by institution 
(Huston et al. 2010), thus the heterogeneity of the analysis could be skewed the conclusions. 
Some considerations can be enhanced, firstly in literature there are not prospectively 
randomized studies which compared the standard follow-up procedures with new imaging 
technologies (e.g. FDG PET) and secondly the worldwide diffusion of hybrid PET/CT is 
approximately recent, thus reducing the available results. 
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9. The future prospective in the follow-up for breast cancer 
In an editorial, Hortobangyi et al. (Hortobangyi et al., 2002) hypothesized that a 
multimodality therapy administered to a group of patients (1-3%) with limited metastatic 
breast cancer could produce long-term disease-free survival or cure. He concluded that, in 
this patient subset, the approach should be curative and not palliative. Consequently, 
intensive postoperative monitoring should be revisited, and large prospective trials are 
needed to identify the optimal candidates. Nevertheless, the subsequent ASCO guidelines 
(Khatcheressian et al., 2006) did not take in these indications. As previously mentioned, it is 
currently recommended that the follow-up of breast cancer patients involves only physical 
examination and conventional mammography; other examinations are recommended only 
in the presence of new symptoms. In the last few years we have seen great developments in 
the biological characterization of breast cancer and in diagnostic technology. These last 
improvements have profoundly changed breast cancer treatment but whether they can 
modify the follow-up for breast cancer treatment in the near future is still unclear. Breast 
cancer is a heterogeneous disease, showing many biological subtypes with different clinical 
features. For example, the positivity to hormone receptors requires different therapeutic 
management to the expression of human epidermal growth factor receptor 2 (HER2)-
positive or a triple negative breast cancer; furthermore, the prognosis is differs widely from 
one case to another. Could the future strategy for breast cancer follow-up be adapted to 
biological characterization? Esserman et al. (Esserman et al., 2011)retrospectively evaluated 
the hormone receptor, the HER2-receptor and the grade from archival blocks of 23 years 
minimum follow-up breast cancer to establish if these features were related to risk and 
timing to recurrence. They observed that in 683 patients with negative-node involvement, 
the outcome risk for hormone receptor-positive and HER2-negative cancer was partitioned 
by tumour grade: lower grade cases had very low early recurrence risk but a 20% fall in ten 
or more years after diagnosis, and higher grade cases had a risk over 20 years. On the 
contrary, triple-negative and HER2-positive cancer showed a primary recurrence within the 
first five years, independently from the grade. Thus the recurrence of disease can be 
stratified based on cancer characteristics. 
The site of relapse can also be different in these subtypes; e.g. Musolino et al. (Musolino et 
al., 2011) conducted a large epidemiological study, concluding that patients with HER2-
positive breast cancer have a significantly higher incidence of central nervous system 
metastasis, especially after treatment with trastuzumab (Herceptin®). Concerning the loco-
regional relapse, breast cancer subtypes have a different risk. Gabos et al. (Gabos et al., 
2010)identified the hormone receptor negative/HER-2 positive status and the triple negative 
status as risks for local relapse, and suggested the possibility of a different follow-up and 
loco-regional treatment for these subtypes. Montagna et al. (Montagna et al., 2011) 
concluded that loco-regional relapse correlates with a high risk of subsequent events, and 
death in particular, in patients with the triple-negative subtype. Based on these 
observations, we can assume that a biological features based approach should be considered 
for follow-up too. 
The technological development in diagnostic techniques could also have a role in follow-up 
changeling. Regarding conventional radiological imaging, MRI could have a role in 
surveillance especially for BRCA1 or BRCA2 positive breast cancer, but currently the best 
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way to integrate mammography and breast MRI and their frequencies are unresolved areas 
of controversy. The major innovations come from nuclear medicine, e.g. the last 
introduction of hybrid devices (e.g. PET/CT and PET/MRI) useful for the evaluation of 
disease represents a great technology development. Furthermore, new devices such as 
positron emission mammography (PEM) represent a technological challenge both in 
primary diagnosis and in loco-regional recurrence, especially in women treated with 
conservative surgery. Moreover, the innovations from the radiopharmaceutical field with 
the introduction, in clinical practice, of new tracers such as 18F-fluoroestradiol (known as 
FES), which is mainly employed for evaluating the hormone receptor expression, a specific 
target for hormonal therapy. 
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